iShares US Healthcare ETF

IYH

Market cap $2.95B

With Q1 earnings season well underway, it was Johnson & Johnson (JNJ) giving investors a peek at how the broader healthcare sector might perform. The healthcare giant beat expectations on Tuesday in revenue ($24.1 billion actual versus $23.6 expected) and earnings per share ($2.70 actual versus $2.66 expected).

After a 50%+ run from lows last April through highs in mid-January, the Biotech group has been trending sideways over the last few months. Biotech hasn't garnered much attention lately, with all the coverage of the Iran War and the AI Doom trade that's been taking down software stocks even as AI infrastructure stocks continue to surge.

Rising oil prices and Middle East tensions are squeezing household finances and weakening consumer sentiment, steering investors toward defensive ETFs.

Are stagflation risks returning as oil-driven inflation rises amid Middle East tensions? Here's how ETFs can help defend portfolios.

With U.S. budget deficits and already elevated debt, the ongoing Middle East war could worsen the fiscal outlook, making defensive ETF strategies worth considering for stability.

Launched on June 12, 2000, the iShares U.S. Healthcare ETF (IYH) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Broad segment of the equity market.

Big Pharma delivered strong Q4 2025 results, with most companies beating revenue and EPS expectations and providing generally solid 2026 guidance. Eli Lilly solidified its leadership in obesity and diabetes, outpacing Novo Nordisk, which faces a sharp 2026 revenue decline amid fierce competition, pricing pressure, and other factors.

From "software-mageddon" to rising AI capex pressuring Big Tech, diversification via defensive and global ETFs gains focus.

The Investment Committee give you their top stocks to watch for the second half.

iShares U.S. Healthcare ETF receives a hold rating due to concerning signals from its top holdings and elevated valuations. IYH's heavy concentration in LLY, JNJ, and ABBV exposes the fund to slowing growth, regulatory pressures, and high forward P/E ratios. GLP-1 market risks, muted growth at JNJ, and ABBV's patent expirations threaten IYH's forward performance and capital appreciation.